Ribomic Inc
TSE:4591
Ribomic Inc
Research & Development
Ribomic Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ribomic Inc
TSE:4591
|
Research & Development
-¥543.5m
|
CAGR 3-Years
30%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-6%
|
|
|
SanBio Co Ltd
TSE:4592
|
Research & Development
-¥2.6B
|
CAGR 3-Years
26%
|
CAGR 5-Years
10%
|
CAGR 10-Years
-7%
|
|
|
GNI Group Ltd
TSE:2160
|
Research & Development
-¥3.3B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-32%
|
|
|
PeptiDream Inc
TSE:4587
|
Research & Development
-¥5B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Takara Bio Inc
TSE:4974
|
Research & Development
-¥6.9B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-5%
|
|
|
C
|
Cuorips Inc
TSE:4894
|
Research & Development
-¥334.1m
|
CAGR 3-Years
-44%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Ribomic Inc
Glance View
RIBOMIC, Inc. engages in the research and development of molecular targeted drugs using Ribonucleic Acid (RNA) aptamers for use in therapeutic fields. The company is headquartered in Minato-Ku, Tokyo-To and currently employs 25 full-time employees. The company went IPO on 2014-09-25. Its drug discovery business is divided into self discovery and co-discovery divisions. Self Drug Discovery division develops aptamer and licenses and out the results to pharmaceutical companies. The Co-Discovery division earns the research expenses paid by the alliance partner for the shared part of co-discovery business with alliance pharmaceutical companies researching aptamer pharmaceutical.
See Also
What is Ribomic Inc's Research & Development?
Research & Development
-543.5m
JPY
Based on the financial report for Sep 30, 2025, Ribomic Inc's Research & Development amounts to -543.5m JPY.
What is Ribomic Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-6%
Over the last year, the Research & Development growth was 21%. The average annual Research & Development growth rates for Ribomic Inc have been 30% over the past three years , 8% over the past five years , and -6% over the past ten years .
